	US 12,102,669 B2
	Compositions for inhibiting teratoma formation and growth comprising TIMP-1 and TIMP-2 as effective components
Sung Hoi Hong, Seoul (KR); and Kyung-Ah Choi, Cheorwon-gun (KR)
Assigned to Korea University Research and Business Foundation, Seoul (KR)
Appl. No. 17/274,657
Filed by Korea University Research and Business Foundation, Seoul (KR)
PCT Filed Jul. 18, 2019, PCT No. PCT/KR2019/008896 § 371(c)(1), (2) Date Mar. 9, 2021, PCT Pub. No. WO2020/054962, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 10-2018-0107637 (KR), filed on Sep. 10, 2018.
Prior Publication US 2022/0031819 A1, Feb. 3, 2022
Int. Cl. A61K 38/57 (2006.01); A61K 35/30 (2015.01); A61K 35/545 (2015.01)

CPC A61K 38/57 (2013.01) [A61K 35/30 (2013.01); A61K 35/545 (2013.01)]

4 Claims

1. A method for inhibiting teratoma formation or growth comprising administering a composition comprising TIMP-1 or TIMP-2 as an active ingredient to a subject in need thereof,

wherein the composition is produced by a process comprising steps of:

(a) immortalizing neural stem cells (NSCs) isolated from a brain ventricular zone; and

(b) obtaining TIMP-1 or TIMP-2 in conditioned medium by culturing the immortalized neural stem cells in a non-inducing medium.